Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis | Zendy

Melinda Gooderham | Zendy; Seth Forman | Zendy; Robert Bissonnette | Zendy; Jean S. Beebe | Zendy; Weidong Zhang | Zendy; C Banfield | Zendy; Linda Zhu | Zendy; Jocelyne Papacharalambous | Zendy; Michael S. Vincent | Zendy; Elena Peeva | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis

Author(s) -

Melinda Gooderham,

Seth Forman,

Robert Bissonnette,

Jean S. Beebe,

Weidong Zhang,

C Banfield,

Linda Zhu,

Jocelyne Papacharalambous,

Michael S. Vincent,

Elena Peeva

Publication year - 2019

Publication title -

jama dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.128

H-Index - 166

eISSN - 2168-6084

pISSN - 2168-6068

DOI - 10.1001/jamadermatol.2019.2855

Subject(s) - medicine , atopic dermatitis , contraindication , placebo , population , randomized controlled trial , clinical trial , janus kinase inhibitor , dermatology , pediatrics , janus kinase , alternative medicine , environmental health , pathology , cytokine

Atopic dermatitis is associated with substantial patient and caregiver burden. Currently available treatments for atopic dermatitis are inadequate or contraindicated for some patients. Abrocitinib (PF-04965842) is an oral Janus kinase 1 selective inhibitor under investigation for the treatment of atopic dermatitis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research